Objective. We looked for an association between the MvaI polymorphism, a recently reported polymorphism on the promoter of the Apo-1/Fas gene, and rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE ) patients.
Apo-1/Fas (CD95) is a transmembrane protein that immune disease characterized by T-lymphocyte accumulation within the synovial compartment. This may result mediates apoptosis and a member of the tumour necrosis from increased migration of activated T cells into the factor/nerve growth factor receptor family which transjoint, proliferation in situ, or inhibition of T-cell death, duces the apoptotic signal into susceptible target cells leading to persistent cell infiltration [2] . The genetic [1] . Recently, Fas and Fas ligand have been considered contribution to RA, particularly severe forms of RA, to play an important role in the development of autohas primarily been attributed to the HLA-DR4 (DRB1) immune diseases, and recent studies have focused on gene in many ethnic populations [3] [4] [5] . It has, however, the apoptosis mediated by these proteins in the causation been shown that the DR region accounts for only 40% of several autoimmune disorders such as rheumatoid of the total genetic susceptibility to RA, suggesting that arthritis (RA) and systemic lupus erythematosus (SLE ) .
genes outside the HLA region are important in disease RA is a common and important rheumatic/autosusceptibility [6, 7] . Non-HLA genes that contribute to RA have not been clearly defined, but a number of from RA patients may be the mechanism for synovial hyperplasia, a characteristic change in RA joint tissues to 68 yr). Eighty-six apparently healthy individuals were also collected as controls. All subjects were Caucasian [8, 9] . Exact relationships among T-cell activation, cytokine expression, synovial hyperplasia and apoptosis and gave written informed consent. are still obscure. A simplified view of tissue growth is DNA preparation an imbalance between proliferation and cell death.
Blood samples from all subjects were obtained for DNA SLE is another important autoimmune disease characextraction and serological tests were carried out to terized by overproduction of autoantibodies and the validate autoantibody profiles. Blood was collected in formation of immune complexes which lead to multiple EDTA tubes and DNA was extracted using the method organ damage. The pathogenesis of the disease is of proteinase K treatment and phenol/chloroform unclear. Recently, much attention has been directed to extraction. the role of Fas-mediated apoptosis, based on findings in the murine lpr lupus-like model which has immunoMvaI polymorphism typing logical abnormalities similar to those in human SLE
The MvaI RFLP was studied by polymerase chain [10] . Studies in human SLE have shown an overreaction (PCR) amplification followed by MvaI restricexpressed Fas gene product and accelerated apoptosis tion enzyme digestion, as previously described [13] . [11] , which may be the mechanism for lymphopenia and
The primer sequences were synthesized according to high titre of autoantibody production noted in SLE [12] .
published data, namely forward primer 5∞-CTACCTAThe mechanism of altered apoptosis and elevated AGAGCTATCTACCGTTC-3∞ and reverse primer Apo-1/Fas gene expression noted in SLE and RA is not 5∞-GGCTGTCCATGTTGTGGCTGC-3∞. For each known, and may be attributed to primary (heritable reaction in 20 ml, 60 ng of DNA template were added factors) or secondary (in response to other stimuli from to the reaction mixture, containing a final concentration host reaction) events. The Apo-1/Fas gene has been of 0.25 mm of each primer, 200 mm dNTPs, 1.0 m mapped to 10q23 and its genomic organization, includMgCl 2 , 50 m KCl 2 , 10 m Tris-HCl (pH 8.5) and ing exons, introns and promoter region, has been charac-0.5 U Taq polymerase (Biotechnology, NSW, Australia). terized. We have recently reported two polymorphisms
The reaction was amplified in an Omni Gene in the promoter region and one of these is a MvaI Thermocycler ( HYBAID, Middlesex, UK ) for 28 cycles restriction length fragment polymorphism (RFLP), the with each cycle consisting of 30 s at 94°C, 30 s at 62°C first polymorphic marker identified in the Apo-1/Fas and 1 min at 72°C. The cycling was preceded by a single gene [13] . The MvaI RFLP is located at the −670 6 min denaturation at 94°C, and followed by a single position from the transcription starting site and results cycle of extension at 72°C for 10 min. Following the from an A G substitution which alters the MvaI restricreaction, 10 ml of reaction mixture from each sample tion site. The polymorphism is situated on a consensus were digested with MvaI restriction enzyme under sequence of the gamma-activated sequence (GAS) and recommended conditions (Boehringer Mannheim). Half thus may have a potential role in gene regulation [14] .
of the product was then loaded onto a 6% nonSince apoptosis has been implicated in RA and SLE, denaturing polyacrylamide gel (acrylamide:biswe hypothesized that the MvaI polymorphism might be acrylamide 49:1). Gels were silver stained and photoa genetic marker for these diseases. The present study graphed. Two polymorphic alleles, allele 1 (188 bp) and examined this hypothesis by analysing associations of allele 2 (233 bp), were produced depending on the the MvaI polymorphism in patients with RA and SLE.
presence of G or A allele at the −670 position.
Statistical analysis

Materials and methods
The distribution of the MvaI genotypes in RA and SLE was compared to that in controls using the x2 test (3 × 2 Subjects contingency table). To compare the frequency of MvaI*1 Two cohorts of RA patients were ascertained for this and 2 alleles or homozygous alleles in each RA or SLE study. The first cohort of patients (n = 103) was subgroup, a 2 × 2 contingency (x2) test was used. The recruited by writing to all Australian rheumatologists odds ratios (OR) and 95% confidence intervals (CI ) who were members of the Australian Rheumatology were used to quantify the association with RA and SLE. Association in New South Wales and Victoria. The diagnosis of RA was defined by the criteria of the American Rheumatism Association (ARA) 1987 criteria Results [15] . A second cohort of RA patients (n = 82) was
The MvaI RFLP in RA patients recruited from St George Hospital clinic and three rheumatological private practices to confirm the findings
The MvaI genotype distribution and allele frequencies in the first cohort of RA patients and healthy controls from the first cohort. The mean age of RA patients was 62 ± 12.3 yr (varying from 23 to 65 yr). A total of 79 are shown in Table 1 . Genotypes of the MvaI RFLP in most of these controls have been previously reported SLE patients were ascertained from eastern Australia by writing to rheumatologists and the diagnosis of SLE [13] . The heterozygous form of MvaI polymorphism was noted in 51% of the normal population, while those was defined by the 1982 ARA criteria [16 ] . The mean age of SLE patients was 52 ± 7.8 yr (varying from 26 homozygous for MvaI*1 and MvaI*2 were in a similar aStatistical analysis was carried out between these RA subgroups and normal controls in Table 1 . aRA patients with the two most common extra-articular features, namely rheumatoid nodules and/or Sjögren's syndrome. bThe mean age at onset in the RA patients was 48 yr. cThe x2 test (3 × 2 contingency) was performed to compare the distribution of MvaI genotypes in RA patients or subgroups with that in the normals. The P value was calculated at 2 degrees of freedom. dThe strength of association between the MvaI alleles and RA subtypes was estimated by the OR with 95% CI denoted in parentheses. eThe 2 × 2 contingency test (x2) was performed to compare the frequency of MvaI alleles in RA patients and the controls. The same test was used to compare MvaI*1 and 2 homozygosity in each subgroup (results detailed in the text).
frequency (26% vs 23%, respectively). There was a zygosity was higher than the MvaI*2 homozygosity in subgroups with positive RF and erosion. The distribuskewing in distribution of the three MvaI genotypes in the RA patients as a whole compared to the controls, tion of MvaI alleles in patients with early onset was not analysed because of the lack of information from these as a result of overrepresentation of the MvaI*2 homozygosity and a reduction of the MvaI*1 homozygosity.
patients. When these patients were divided by sex, the skewed The MvaI RFLP in SLE patients distribution was more profound in female patients than male patients. The skewed MvaI genotype distribution
The MvaI RFLP was examined in 79 sporadic SLE patients (Table 3 ). The distribution of the MvaI RFLP in female patients was not statistically significant; however, the frequency of the MvaI*2 allele in female RA genotypes in these SLE patients was comparable to that in controls. Since SLE is a heterogeneous disorder with patients was found to be significantly higher than controls ( x2 = 4.36, P < 0.03, OR 1.6, 95% CI 1.0-2.4).
diverse clinical manifestations, the MvaI genotype was then examined in different SLE subgroups. Increased When the patients were classified into clinical subtypes, the skewed genotype distribution was also noted in RA homozygous MvaI*2 allele was noted in SLE patients with malar rash, oral ulceration, photosensitivity, arthpatients with systemic involvement (as judged by extraarticular disease features, such as nodules and Sjö gren's ritis, renal disease and neuropsychosis. However, neither the MvaI*2 allele frequency nor MvaI*2 homozygosity syndrome) or with progressive disease (as assessed by the presence of erosions), due to the increased MvaI*2 was significantly higher in these subgroups compared with the controls. We subsequently examined the freallele in all these subgroups. The increased frequency of the MvaI*2 allele observed in patients with extraquency of MvaI*2 homozygous carriage in patients with and without each SLE clinical subgroup ( Table 4) . It articular features was statistically significant ( x2 = 4.18, P < 0.04, OR 1.6, 95% CI 1.1-2.6; Table 1 ).
was shown that MvaI*2 homozygous carriage was significantly more common in patients with photosensitivSince the homozygous MvaI*2 allele was found to be associated with certain RA subgroups, we then examined ity or oral ulcers compared to patients without these features (risk for photosensitivity: OR = 5.75, 95% CI whether individuals with this marker may be predisposed to RA and therefore had early onset of the disease. The 1.2-27.0, P = 0.02; risk for oral ulcers: OR = 4.0, 95% CI 1.3-12.1, P = 0.01). Such differences were not noted mean age at onset of RA patients in this study was 48 yr. Patients were divided into two age at onset groups:
in those subgroups with MvaI*1 homozygosity. No correlation between the MvaI alleles and ANA was <48 yr and >48 yr ( Table 1 ). The MvaI genotype distribution in RA patients with early onset was significantly found (data not shown). skewed compared to the normals ( x2 = 6.1, P = 0.047, d.f. = 2), as a result of overrepresentation of MvaI*2 Discussion homozygosity (patients vs controls: 42% vs 23%). Such a skewed distribution of the MvaI genotype was not Immunogenetic markers, particularly in combination with seropositivity, offer the possibility of identifying at noted in the patients with later onset. The frequency of the MvaI*2 allele was also found to be significantly an early stage of the disease patients who are at risk of a poor outcome. It has been shown that HLA typing is higher than the controls (65% vs 49%, P = 0.01, OR 2.0, 95% CI 1.1-3.3). The MvaI*2 homozygous carriers useful for risk assessment for RA, but not so much for SLE. However, the HLA-DR4 (DRB1) gene accounts were found to have a significantly higher risk for early onset than non-MvaI*2 homozygous carriers (P = 0.03, for only 30-60% of all RA cases, suggesting that there are other genetic markers associated with RA OR = 2.37, 95% CI 1.0-5.3). The result suggested that individuals carrying the MvaI*2 allele were predisposed susceptibility. This study studied a new genetic marker, MvaI polyto RA and thus likely to develop the disease earlier.
To confirm the above findings, another cohort of RA morphism on the Apo-1/Fas promoter gene, in RA and SLE patients; however, the results from two cohorts of patients was ascertained from St George Hospital, Sydney, for testing. These patients (n = 82) were part RA patients were not consistent. In the first cohort of RA patients, the MvaI genotype distribution in RA of an ongoing longitudinal study of HLA-DR status and RA outcome, and therefore the designed questionpatients, as well as in RA subgroups with erosions and extra-articular features, was skewed compared to the naire was somewhat different to the one used in the first cohort of RA patients. Relationships between manifestcontrols, as a result of increased MvaI*2 homozygosity and decreased MvaI*1 homozygosity. The overrepreations, such as age, gender and rheumatoid factor (RF ), and MvaI allele status were examined ( Table 2) . Of sentation of the MvaI*2 homozygosity gave rise to an increased MvaI*2 frequency in RA as a whole, particuthese 82 patients, there were 58 who had full clinical information in relation to the above manifestation. The larly in female RA patients (P = 0.035) or patients with extra-articular involvement (P = 0.04). In addition, the results from this cohort of patients did not replicate the findings from the first cohort of RA patients. For observation of the increased MvaI*2 homozygosity in these patients suggested that there might be a gene dose example, there was no trend of increased MvaI*2 allele or MvaI*2 homozygosity in the overall patients and, effect on full RA expression. The skewed distribution of MvaI genotypes and high frequency of MvaI*2 allele interestingly, the MvaI*2 homozygosity was markedly decreased (8%) in the male patients. The MvaI*1 homowere most evident in the patients whose age at onset was under the mean age at onset (P = 0.01), indicating different purposes and therefore patient selection criteria could be different or biased. For example, patients that the MvaI*2 allele carriers might also be predisposed to RA and therefore develop the disease earlier.
collected from major teaching hospitals had a more severe and longer ongoing disease than patients recruited When the second cohort patients from St George Hospital, Sydney, were studied, the same results were from private practice locations. Thirdly, the contribution of the MvaI polymorphism may be minor and not not replicated. In these overall patients, MvaI*1 homozygosity was slightly increased compared with MvaI*2 obvious in a small number of patients. All such arguments need further investigation. homozygosity. Furthermore, patients with positive RF and erosions did not appear to have different MvaI With regard to the genetics of SLE, there has been a renewed interest in non-HLA loci in disease susceptibilallelic distribution compared to controls. There were no associations between any alleles and RA subgroups. It ity [17] . The Apo-1/Fas gene is suggested to play a role in SLE by studies which have shown an increase in is not clear why there were inconsistent results from the two populations of patients. Several factors may contribapoptosis and elevated expression of the Fas gene in vivo with unknown mechanism. The contribution of the ute to this discrepancy. Population stratification phenomenon, a well-known factor, is most likely to affect germline Apo-1/Fas gene polymorphism to SLE has never been explored. Here, we examined MvaI association studies in different populations. Secondly, patients from these two populations were recruited for polymorphism in SLE and showed that the MvaI*2 allele was also increased in some SLE patients (those still not known and it is reasonable to speculate that various kinds of cytokines noted in SLE and RA may with malar rash, oral ulcer, photosensitivity, arthritis, have important roles in the regulation of Apo-1/Fas renal disease and neuropsychosis) compared with the gene expression. Owing to the uncertainty of the role of normal controls, but this did not reach a significant the Apo-1/Fas MvaI polymorphism in RA or SLE, this level. The failure to detect an association between study raises the question of whether this polymorphism MvaI*2 homozygosity and the above subtypes may be at the STAT binding site may be involved in differential due to the small size of samples and does not exclude gene regulation. the possibility that MvaI*2 homozygosity may be a risk factor for SLE patients with these subgroups. A followup study in a larger sample will be necessary to elucidate the issue further and to confirm those associations found
